Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzuloparib plus AA-P in mCRPC
NCT04691804Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of fluzoparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hengrui. Started Mar 2021; status: active, not recruiting.
02
Drugs
fluzoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04691804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691804.